// App-Quantinova.ai

300 : Moving from early to moderate or advanced biochemical disease stage during follow‐up is associated with an increasing risk of clinical events in primary biliary cholangitis patients.

Researchers

Presenter

  • Nikolaos K. Gatselis

Principal Investigators

  • Kalliopi Zachou

  • Willem J. Lammers

  • Harry L. Janssen

  • Gideon Hirschfield

  • Christophe Corpechot

  • Keith D. Lindor

  • Pietro Invernizzi

  • Marlyn J. Mayo

  • Pier Maria Battezzati

  • Annarosa Floreani

  • Albert Pares

  • Vasiliki Ligoura

  • Frederik Neve ns

  • Andrew Mason

  • Kris V. Kowdley

  • Cyriel Y. Ponsioen

  • Tony Bruns

  • Douglas Thorburn

  • Xavier Verhelst

  • Maren H. Harms

  • Henk R. van Buuren

  • Bettina E. Hansen

  • George Dalekos

Medical Centers

  • Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece

  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands

  • Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto,

  • NIHR Biomedical Research Unit and The Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom

  • Centre de Référence des Maladies Inflammatoires des VoiesBiliaires, Hôpital Saint‐Antoine, Paris, France

  • Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

  • Arizona State University, Phoenix, AZ

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

  • Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX

  • Department of Biosciences, Universit degli studi di Milano, Milano, Italy

  • Department of Surgery, Oncology and Gastroenterology -DiSCOG, University of Padova, Padova, Italy

  • Liver Unit, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Gastroenterology and Liver Unit, Univeristy of Alberta, Edmonton, AB, Canada

  • Liver Center Swedish Medical Center, Seattle, WA

  • Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands

  • Department of Gastroenterology and Hepatology, University of Duisburg-Essen, Essen, Germany

  • Sheila Sherlock Liver Centre, Royal Free Hospital London,

  • Department of Gastroenterology , Univ. Hospitals Leuven, Leuven, Belgium

Locations

  • Greece

  • Netherlands

  • Canada

  • United Kingdom

  • France

  • United States

  • Italy

  • Spain

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Primary biliary cirrhosis

  • Liver cancer

  • Ascending cholangitis

  • Solid malignancies

Biomarkers

  • Human albumin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved